UNSPSC 51385601: Imidazole salicylate

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C7H6O3.C3H4N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4JVD4X01MJ, chemically known as salicylic acid, compound with imidazole (1:1) but generally known as imidazole salicylate, which bears US NIH Compound Identifier 37425. European Medicines Agency schedules Imidazole salicylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08145MIG.

UNSPSC 51385601 Imidazole salicylate is a Commodity code whose scope in recent state and local procurement covers pharmaceutical products and drug-related health supplies purchased through competitive bidding and cooperative procurement mechanisms. The actual work being solicited under this code spans generic multi-source pharmaceuticals, over-the-counter products, and specialized health interventions such as naloxone and drug deactivation systems. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing consortia (Minnesota Multistate Cooperative Purchasing Alliance, MMCAP). These entities procure pharmaceuticals and health products to support community health initiatives, pharmacy benefit programs, and employee health plans across multiple jurisdictions.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, Sanford, with a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription programs and vendor capabilities for therapeutic pharmacy initiatives, with response due April 3, 2026. MMCAP, administered by the Minnesota Department of Administration, released RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products across participating state and local government facilities, with proposals due March 26, 2026 and contract performance beginning July 1, 2026. Vendors responding to MMCAP contracts must maintain relationships with authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, Morris & Dickson), comply with cGMP and DSCSA requirements, hold commercial general liability insurance of $5,000,000 per occurrence, and pay a 3 percent administrative fee on all purchases.